Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oklahoma Acquires New Imaging Technology

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Protea Biosciences have announced that the University of Oklahoma’s Institute for Natural Products Applications and Research Technologies (INPART) has acquired the LAESI DP1000 biomolecular imaging system.

INPART is directed by Robert Cichewicz, PhD., associate professor in the Department of Chemistry and Biochemistry. The instrument will be used for the Institute’s natural products-based drug discovery operations. 

Cichewicz will be using this new instrument to characterize newly discovered compounds produced by fungi and other microbes, in an effort to develop new treatments for life-threatening infections. LAESI (short for Laser Ablation Electrospray Ionization) is designed to rapidly generate imaging profiles of the biomolecules present in cells and to analyze tissue sections identical to those used in pathology. The LAESI DP-1000 is intended to allow the direct identification of biomolecules in living cells and bacterial colonies, with analysis completed in seconds to minutes. Thus, molecular changes that occur in cells over time can be identified and tracked. 

Cichewicz said, “This instrument is designed to allow us to examine the changes that occur in fungal and bacterial colonies such as their production of secondary metabolites, permitting us to identify and characterize new candidate antimicrobial compounds.” 

Cichewicz’s laboratory studies microbial natural products, which are the unique compounds produced by fungi and bacteria. These compounds play important roles in helping microorganisms adapt to their environment, and they exhibit a diverse array of novel structures. The Cichewicz Laboratory focuses on using secondary metabolites from fungi and bacteria for the treatment of human diseases such as life-threatening infections and cancer. 

The LAESI DP1000, developed by Protea Biosciences, was selected by an independent judging panel and the editors of R&D Magazine to receive a prestigious 2012 R&D 100 Award, as one of the 100 most technologically significant products introduced in the past year. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protea Announces License Agreement with Yale
Company has announced an exclusive license agreement with Yale for new technology for detecting malignant melanoma skin cancer.
Tuesday, April 26, 2016
Protea, MSK, Dana-Farber Enter Collaborative Research Agreement
Protea's LAESI technology to be used to profile cancer cells to improve diagnosis and treatment selection
Wednesday, April 30, 2014
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!